These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31873735)

  • 1. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
    Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
    Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.
    Bredemeier M; Lopes LM; Eisenreich MA; Hickmann S; Bongiorno GK; d'Avila R; Morsch ALB; da Silva Stein F; Campos GGD
    BMC Cardiovasc Disord; 2018 Feb; 18(1):24. PubMed ID: 29415653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
    Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
    Becker MA; MacDonald PA; Hunt BJ; Jackson RL
    Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
    White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
    N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
    Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
    Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
    Shin A; Choi SR; Han M; Ha YJ; Lee YJ; Lee EB; Kang EH
    Semin Arthritis Rheum; 2022 Oct; 56():152080. PubMed ID: 35973263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
    BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
    So MW; Kim AR; Lee SG
    Int J Rheum Dis; 2023 Sep; 26(9):1770-1778. PubMed ID: 37431263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
    Weisshaar S; Litschauer B; Reichardt B; Gruber F; Leitner S; Sibinovic S; Kossmeier M; Wolzt M
    Rheumatol Int; 2022 Sep; 42(9):1597-1603. PubMed ID: 35589988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
    Jeong H; Choi E; Suh A; Yoo M; Kim B
    Rheumatol Int; 2023 Feb; 43(2):265-281. PubMed ID: 36346443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
    Carroll MB; Smith DM; Shaak TL
    Rheumatol Int; 2017 Mar; 37(3):445-453. PubMed ID: 27798726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febuxostat versus allopurinol for gout.
    Gelber AC
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
    Deng JH; Lai PH; Xie LS; Qiu SS; Qiu DS; Zhang JX
    Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.